Setting R&D priorities and investment, redesigning operating models and governance, and lifting productivity across the pipeline.
Target and indication selection, biomarker strategy and the step from bench to first-in-human, increasingly supported by AI-enabled platforms.
Programme and trial strategy, indication sequencing and integrated evidence plans that balance speed, cost and probability of success.
Protocol and site design, faster start-up and enrolment, decentralised trial models and the oversight of CROs and vendors.
Global regulatory pathways, agency interactions, risk management and inspection-ready pharmacovigilance.
Consultancies advising on pipeline strategy, development productivity, clinical operations and R&D operating models.